Open AccessDetection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients1
Author(s) -
Maria Pia Pistillo,
Pier Luigi Tazzari,
Francesca Bonifazi,
Giuseppe Bandini,
Tomohiro Kato,
Toshihiro Matsui,
Kusuki Nishioka,
Roberto Conte,
Giovanni Battista Ferrara
Publication year - 2002
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-200204270-00019
Subject(s) - cd80 , cd86 , ctla 4 , t cell , antibody , microbiology and biotechnology , immunology , lymphocyte , cd28 , chemistry , biology , cytotoxic t cell , in vitro , immune system , biochemistry , cd40
T-cell costimulation has been shown to provide positive signals for T-cell activation and generation of effector activity. In this study, we analyzed the presence of antibodies (Abs) against the T-lymphocyte costimulatory molecules CD28, CTLA-4, CD80, and CD86 in anti-T-lymphocyte (ATG) and antithymocyte (TMG) globulin preparations to address their mechanism of action. We focused our attention on the role of CTLA-4-specific Abs in the immunosuppressive effect of ATG/TMG, because anti-CTLA-4 agonistic Abs may suppress T-cell proliferation and nonagonistic Abs may lead to T-cell depletion through an Ab-dependent cell cytotoxicity mechanism.